Literature DB >> 9009245

Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes.

V Shetty1, S Mundle, S Alvi, M Showel, L Broady-Robinson, S Dar, R Borok, J Showel, S Gregory, S Rifkin, S Gezer, A Parcharidou, P Venugopal, R Shah, B Hernandez, M Klein, D Alston, E Robin, C Dominquez, A Raza.   

Abstract

Extensive apoptosis or programmed cell death (PCD) of both hematopoietic (erythroid, myeloid, megakaryocytic) and stromal cells in myelodysplastic syndromes (MDS) cancels the high birth-rate resulting in ineffective hematopoiesis and has been demonstrated as the probable basis for peripheral cytopenias in MDS by our group. It is proposed that factors present in the microenvironment are inducing apoptosis in all the cells whether stromal or parenchymal. To investigate this hypothesis further, bone marrow biopsies from 46 MDS patients and eight normal individuals were examined for the presence of three cytokines, tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta) and granulocyte macrophage-colony stimulating factor (GM-CSF) and one cellular component, macrophages, by the use of monoclonal antibodies immunohistochemically. Results showed the presence of TNF-alpha and TGF-beta in 41/46 and 40/46 cases of MDS respectively, while only 15 cases showed the presence of GM-CSF. Further a significant direct relationship was found between the degree of TNF-alpha and the incidence of PCD (p= 0.0015). Patients who showed high PCD also had an elevated TNF-alpha level. Thus, the expression of high amounts of TNF-alpha and TGF-beta and low amounts of the viability factor GM-CSF may be responsible for the high incidence of PCD leading to ineffective hematopoiesis in MDS. Future studies will be directed at attempting to reverse the lesion in MDS by using anti-TNF-alpha drugs such as pentoxifylline.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9009245     DOI: 10.1016/s0145-2126(96)00008-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  34 in total

Review 1.  Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes.

Authors:  Jingya Wang; Zhijian Xiao
Journal:  Stem Cell Investig       Date:  2014-08-21

2.  Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.

Authors:  Steven M Kornblau; David McCue; Neera Singh; Wenjing Chen; Zeev Estrov; Kevin R Coombes
Journal:  Blood       Date:  2010-08-02       Impact factor: 22.113

Review 3.  Immunologic aspects of hypoplastic myelodysplastic syndrome.

Authors:  Rodrigo T Calado
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

4.  Detection of TNFalpha expression in the bone marrow and determination of TNFalpha production of peripheral blood mononuclear cells in myelodysplastic syndrome.

Authors:  L Molnár; T Berki; A Hussain; P Németh; H Losonczy
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

5.  The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.

Authors:  U Testa; F Grignani; P Samoggia; C Zanetti; R Riccioni; F Lo Coco; D Diverio; N Felli; C G Passerini; M Grell; P G Pelicci; C Peschle
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

6.  Enhanced growth of myelodysplastic colonies in hypoxic conditions.

Authors:  James Edwin Thompson; Joseph Patrick Conlon; Xiaowei Yang; Patricia Vanessa Sanchez; Martin Carroll
Journal:  Exp Hematol       Date:  2007-01       Impact factor: 3.084

Review 7.  Molecular pathogenesis of MDS.

Authors:  Hisamaru Hirai
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

8.  Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.

Authors:  Wendy W Pang; John V Pluvinage; Elizabeth A Price; Kunju Sridhar; Daniel A Arber; Peter L Greenberg; Stanley L Schrier; Christopher Y Park; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-06       Impact factor: 11.205

Review 9.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

10.  NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).

Authors:  Daniella M B Kerbauy; Vladimir Lesnikov; Nissa Abbasi; Sudeshna Seal; Bart Scott; H Joachim Deeg
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.